Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,375.20
(
-1.46%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.44
(
3.84%
)
Bitcoin
69,938.67
(
0.06%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 176774

Thursday, 01/29/2015 6:29:59 PM

Thursday, January 29, 2015 6:29:59 PM

Post# of 257264
BMY/GILD—FDA approves Evotaz FDC (Reyataz + Cobicstat):

http://finance.yahoo.com/news/u-food-drug-administration-approves-221900783.html

GILD’s Cobicstat (a constituent of Stribild and Complera) is an alternative to ritonavir for boosting BMY’s HIV protease inhibitor, Reyataz.

BMY will book sales of Evotaz; the companies haven’t disclosed how much GILD will be paid for the Cobicstat component.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today